Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
See All Experts
story of the week
Published in Oncology and
2 other channels

Journal Scan / Research · August 13, 2014

ERSPC: Screening and Prostate Cancer Mortality

The Lancet

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Peter Lin MD, CCFP

The Lancet
Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up
Lancet 2014 Aug 07;[EPub Ahead of Print], FH Schröder, J Hugosson, MJ Roobol, TL Tammela, M Zappa, V Nelen, M Kwiatkowski, M Lujan, L Määttänen, H Lilja, LJ Denis, F Recker, A Paez, CH Bangma, S Carlsson, D Puliti, A Villers, X Rebillard, M Hakama, UH Stenman, P Kujala, K Taari, G Aus, A Huber, TH van der Kwast, RH van Schaik, HJ de Koning, SM Moss, A Auvinen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated